AbbVie Inc. Study M16-006

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of different doses of risankizumab and determine how well it works in managing symptoms in subjects with moderate to severe Crohn disease. Risankizumab is an investigational drug. This means it has not been approved by the US Food and Drug Administration (FDA). Risankizumab is made in the laboratory and is a monoclonal antibody which means that it is the same as a protein (chemical) which is in your body, called an antibody. It works by blocking the actions of a protein known as Interleukin 23. Interleukin 23 is involved in the immune response and plays an important role in the development of chronic inflammation. Risankizumab is being studied in patients with inflammatory bowel disease and other inflammatory diseases.


Clinical Study Identifier: s17-00158
ClinicalTrials.gov Identifier: NCT03105128
Principal Investigator: David P Hudesman.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.